| Outcome Measures: |
Primary: Number of subjects with clinically significant changes in physical examinations, laboratory safety tests, and vital signs, Assessed over 29 days|Number of subjects with treatment-emergent adverse events, Assessed over 29 days | Secondary: Maximum observed concentration (Cmax) of darbepoetin alfa, Assessed predose and at 6, 24, 48, 72, and 168 hours postdose|Time at which maximum concentration is observed (Tmax) of darbepoetin alfa, Assessed predose and at 6, 24, 48, 72, and 168 hours postdose|Area under the concentration curve (AUC) of darbepoetin alfa, Assessed predose and at 6, 24, 48, 72, and 168 hours postdose|Terminal half-life (t½) of darbepoetin alfa, Assessed predose and at 6, 24, 48, 72, and 168 hours postdose|Clearance (CL) of darbepoetin alfa, Assessed predose and at 6, 24, 48, 72, and 168 hours postdose|Change in reticulocytes, Assessed from baseline to day 8|Change in reticulocytes, Assessed from baseline to day 29|Change in hemoglobin concentration, Assessed from baseline to day 8|Change in hemoglobin concentration, Assessed from baseline to day 29|Change in iron, Assessed from baseline to day 29|Change in ferritin, Assessed from baseline to day 29|Change in transferrin saturation, Assessed from baseline to day 29
|
